Sponsored by

Poster Number Index
Click on one of the following number ranges below to display a list of posters.
Click the checkbox next to each item to bookmark.

101 – 200 | 201 – 300 | 301 – 400 | 401 – 500 | 501 – 600 | 601 – 700 | 701 – 800
801 – 900 | 901 – 1000 | 1001 – 1100 | 1101 – 1200 | 2001 – 2100 | 2101 – 2200 | 3001 – 3100
3101 – 3200 | 4001 – 4100 | 4101 – 4200 | 5001 – 5100 | 5101 – 5200 | 6001 – 6100 | 6101 – 6152

  [5101] The addition of zoledronic acid to neoadjuvant chemotherapy may influence pathological response – exploratory evidence for direct anti-tumor activity in breast cancer.
  [5102] Biomarkers associated with pathologic complete response to neoadjuvant chemotherapy in women with locally advanced breast cancer: results from the I-SPY TRIAL (CALGB 150007/150012 & ACRIN 6657).
  [5103] Clinical impact of pathological axillary downstaging in locally advanced breast cancer after primary systemic chemotherapy.
  [5105] Remarkable complete pathologic response rate after preoperative paclitaxel, gemcitabine, and trastuzumab chemotherapy in HER2 positive stage II/III breast cancer: a phase II multicenter study.
  [5106] Neoadjuvant endocrine treatment. Long term outcome of a series of patients treated at the Institut Bergonié, Bordeaux.
  [5107] Complete pathological response according to hormonal status, c-erbB2 and P53 in two neoadjuvant treatments in locally advanced breast cancers.
  [5109] Weekly paclitaxel improved pathological response of primary chemotherapy compared with standard 3 weeks schedule.
  [5110] NCCTG N0338: effect of docetaxel and carboplatin on VEGF, PGE2, and immune cells in patients with stage II or III breast cancer.
  [5111] Sentinel lymph node biopsy (SLNB) prior to primary chemotherapy (PC) in breast cancer patients.
  [5112] Lapatax: a phase I study of neoadjuvant lapatinib combined with docetaxel in Her2/neu overexpressing breast cancer (BC). EORTC protocol 10054.
  [5113] Changes in ER beta versus ER alpha in short-term studies of antiestrogen therapies.
  [5114] Bevacizumab combined with chemotherapy significantly improves pathologic complete response in patients with operable or locally advanced breast cancer.
  [5115] Multicenter phase II study of neoadjuvant capecitabine (X), docetaxel (T) ± trastuzumab (H) for patients (pts) with locally advanced breast cancer (LABC): final analysis.
  [5116] Preliminary progression free survival and SPARC tumor correlatives from a phase II neoadjuvant trial of gemcitabine, epirubicin, and nab paclitaxel.
  [5117] Phase II study of a 3-weekly liposome-encapsulated doxorubicin/docetaxel/pegfligrastrim in combination with weekly trastuzumab as primary treatment in HER2 positive early stage breast cancer patients (II-IIIa). GEICAM 2003-03 study.
  [5119] Multicentric study with neoadjuvant endocrine therapy for breast conserving surgery. Experience in Mexico.
  [5120] Accuracy of DCE – MRI in predicting response in patients treated with taxane based neoadjuvant chemotherapy.
  [5121] The response to neoadjuvant chemotherapy and prognosis of triple-negative breast cancer patients.
  [5122] A randomized phase II trial of preoperative docetaxel (D) and capecitabine (C) given sequentially or concurrently for Her2 negative breast cancers.
  [5123] Is the sentinel lymph node biopsy accurate for patients with initially clinically axilla-positive locally advanced breast cancer after neoadjuvant chemotherapy?
  [5125] A randomised controlled trial to evaluate both the role and optimal fractionation of radiotherapy in the conservative management of early breast cancer.
  [5126] Three year analysis of patient demographics, treatment efficacy, cosmesis, and toxicity by the American Society of Breast Surgeons MammoSite® registry in patients (age <50 or ≥ 50) treated with accelerated partial breast irradiation (APBI).
  [5127] Triple negative breast cancer confers higher recurrence rates after breast conserving therapy.
  [5128] No positive effect of postmastectomy radiotherapy on mortality at 20 years in pre menopausal women with stage II breast cancer also treated with adjuvant oral cyclophopsphamide. South Sweden Breast Cancer Group, trial SBII:I.
  [5130] Prone versus supine breast irradiation in early stage breast cancer patients.
  [5132] Preliminary result of a mono-institutional, prospective study of skin and cardiac toxicities in breast cancer patients treated by concurrent adjuvant trastuzumab and radiotherapy involving in most cases the internal mammary chain.
  [5134] Comparative analysis of the post-lumpectomy target volume versus the use of pre-lumpectomy tumor volume for early stage breast cancer: implications for the future.
  [5135] Radiotherapeutic management of isolated local-regional recurrence following mastectomy.
  [5137] Ovarian ablation by radiotherapy; is it still an option for the ovarian function suppression in endocrine responsive premenopausal breast cancer patients?
  [5138] Initial radiation experience evaluating early tolerance and toxicities in patients undergoing accelerated partial breast irradiation using the Contura™ multi-lumen balloon (MLB) breast brachytherapy catheter.
  [5140] A prospective nonrandomize study comparing electron intraoperative boost radiotherapy versus postoperative interstitional brachytherapy in patients having breast conserving surgery and adjuvant external beam radiotherapy.
  [5141] A Contura™ catheter provides dosimetric advantages over a MammoSite™ catheter for accelerated partial breast irradiation.
  [5142] Patterns of care study of breast-conserving therapy in Japan: comparison of the treatment process among 1995-1997, 1999-2001 and 2003-2005 surveys.
  [5143] Local recurrence rates in the conserved breast after MRI targeted radiotherapy.
  [5144] Comparison of iridium implant boost versus electron boost as a component of breast conservation treatment for early-stage breast carcinoma.
  [5145] Long term disease control outcomes for partial breast irradiation using MammoSite brachytherapy.
  [5146] Partial breast irradiation with electron beam for patients with breast cancer submitted to conservative surgery.
  [5147] Do conventional radiotherapy fields irradiate the regional lymphatics correctly in patients with breast cancer?
  [5148] Utilization of tomotherapy-based topotherapy for emerging breast radiation techniques: boost integration and accelerated partial breast irradiation.
  [5150] Objective cosmetic analyses after breast surgery with the breast analysing tool (BAT) correlates with subjective and objective scores: a new tool for prospective trials.
  [5151] Breast conservation in the treatment of T2 breast tumors – analysis of 1988-2003 SEER data.
  [5152] Breast conservation: factors predictive of residual disease following reoperation for narrow surgical margins.
  [5154] Oncoplastic surgery for breast cancer: an alternative to mastectomy?
  [5155] Radiofrequency ablation treatment for small breast cancer.
  [5156] Ipsilateral breast tumor recurrence rates in breast cancer patients treated with preoperative chemotherapy, breast conserving surgery and intraoperative radiotherapy with electrons.
  [5157] Immediate breast reconstruction with contralateral pectoralis major myomammary flap for breast conserving surgery.
  [5158] Oncoplasty for lateral breast cancers.

 
 

Poster Sessions | Support | FAQ | Privacy Policy

San Antonio Breast Cancer Symposium
7703 Floyd Curl Dr. Mail Code 8224
San Antonio, TX 78229 USA
http://www.sabcs.org
Technical Support • © 2010 Marathon Multimedia, a Learner’s Digest International business. • All rights reserved